



Posted 16 August 2018

ASX-listed biotech Actinogen expects to complete patient enrolment for its phase 2 study of Xanamem in the treatment of mild Alzheimer's disease later this year with top-line results in less than 12 months, CEO Bill Ketelbey says.

In July the company added five sites in the US to accelerate recruitment, making a total of 20 study locations across the US as well as Europe and Australia.

"The US has by far the largest potential patient population and the addition of the new study sites in this region has provided positive impetus to patient recruitment," Ketelbey said.

The US has the most sites, sitting at 14, following with six in Europe and five in Australia.

Across the sites, 75 per cent of the total 174 patients have now enrolled in the 12-week, randomised, placebo-controlled trial.

The company has also partnered with dementia app developer Mindmate, which is expected to accelerate recruitment.

Although Alzheimer treatments have failed one after another, Xanamem's novel mechanism of action, which blocks excess production of cortisol, sets it apart from other treatments.

Tiffany Walker